Why MedTech Doesn’t Sell After Approval
FDA approval feels like the finish line. It’s not.
In this episode, we break down one of the most dangerous assumptions in MedTech go-to-market: that regulatory approval leads to commercial success.
It doesn’t.
We introduce the concept of buyability - the real-world ability of hospitals and healthcare systems to adopt, pay for, and implement a product under actual economic and operational conditions.
You’ll hear why:
physician interest doesn’t equal revenue
strong clinical results can still fail commercially
reimbursement is not a detail - it’s market structure
and why most pipelines in…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.